Foghorn slumps as FDA deepens clinical hold on cancer drug trial
23/08/2022 13:26
** Shares of Foghorn Therapeutics Inc FHTX.O slide 29% to
$10.43 premarket
** Co says U.S. FDA has placed a full clinical hold on
early-stage dose escalation study of blood cancer drug FHD-286,
months after trial was put on a partial hold due to one death
urn:newsml:reuters.com:*:nGNX5fRN8Y urn:newsml:reuters.com:*:nL3N2XB2YM
** The full hold comes after observation of additional
suspected cases of fatal differentiation syndrome, which is a
complication associated with some leukemia therapies
** Says FDA has additional questions and requires further
analyses before the clinical hold on study may be lifted
** As of last close, stock down ~36% YTD
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))